← Russell 3000 cross-section

IMNM Immunome Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$3.3bn
Revenue TTM
$0m
Net income TTM
$-254m
Free cash flow
$-219m
Composite score
33.0
Sector rank
#1344

Valuation

P / E
EV / EBITDA
EV / sales
FCF yield
-6.72%
Earnings yield vs 10-yr
-12.53pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
EBITDA margin
ROE
-48.4%
ROIC
-5,316.8%
Revenue growth
-100.0%

Insider activity, last 90 days

Net open-market
$-15.68m
Buyers
1
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Revenue recognized under the Collaboration Agreement consisted of payments received from AbbVie and was recognized over the performance period. For example, product candidates in later stages of clinical development generally have higher costs than those in earlier stages of development, primarily due to the size and cost of later-stage clinical trials compared to early development activities. Results of operations Comparison of the three months ended June 30, 2026 and 2025 The following table summarizes our results of operations for the periods presented (in thousands): (1) Amounts include non-cash share-based compensation expense as follows (in thousands): Collaboration revenue There was n …Immunome Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →